Breyanzi (Lisocabtagene Maraleucel) for Lymphoma | MyLymphomaTeam

Connect with others who understand.

sign up Log in
Resources
About MyLymphomaTeam
Powered By

Overview
Breyanzi is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B. It is also approved for relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies, including a Bruton’s tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor. Additionally, Breyanzi is approved for relapsed or refractory follicular lymphoma (FL) after two or more prior therapies, and for relapsed or refractory mantle cell lymphoma (MCL) after at least two prior lines of systemic therapy, including a BTK inhibitor. Breyanzi is also known by its drug name, lisocabtagene maraleucel.

Breyanzi is a type of immunotherapy called chimeric antigen receptor (CAR) T-cell therapy. Breyanzi is made from a person’s own T cells that have been harvested and genetically engineered to target lymphoma cells. Breyanzi is believed to work by attacking and killing lymphoma cells.

How do I take it?
Prescribing information states that Breyanzi is administered intravenously as a single infusion after completing lymphodepleting chemotherapy. This process involves harvesting the treatment recipient’s T cells, genetically modifying them, and then infusing them back into the individual. The manufacturing process takes three to four weeks. Premedication with acetaminophen and an H1 antihistamine is recommended before the infusion. Breyanzi should be taken exactly as prescribed by a health care provider.

Side effects
The FDA-approved label for Breyanzi lists common side effects including fever, fatigue, nausea, musculoskeletal pain, and cytokine release syndrome (CRS). CRS is both common and potentially severe in people who take Breyanzi. CRS, which can be potentially fatal, can include fever, low blood pressure, rapid heart beat, and neurological side effects such as seizures, hallucinations, and tremors. Also common are decreases in neutrophil counts, white blood cells, hemoglobin, platelet counts, and lymphocyte counts.

Rare but serious side effects may include secondary hematological malignancies (new blood cancers), prolonged cytopenias (low blood cell counts), serious infections, hypersensitivity reactions, and neurologic toxicities (nerve damage).

For more details about this treatment, visit:

Label: Breyanzi — Lisocabtagene Maraleucel Kit — DailyMed

Lisocabtagene Maraleucel Injection — DailyMed

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in